Professor Vlado Perkovic

MBBS, PhD, FRACP, FASN
Professor, Sydney Medical School
Executive Director, The George Institute of Global Health Australia
NHMRC Senior Research Fellow
Staff Specialist, Nephrology, Royal North Shore Hospital

Telephone +61 2 8238 2418
Fax +61 2 9993 4502

Map

Biographical details

Professor Vlado Perkovic is a nephrologist and internationally renowned researcher in kidney disease who heads the George Institute of Global Health Australia. He conducts and leads international clinical trials and meta-analyses on kidney and cardiovascular disease, diabetes and blood pressure management. Underscoring his commitment to building the evidence for kidney and cardiovascular disease treatment and prevention, Professor Perkovic’s research broadly covers three themes: preventing and treating (i) kidney disease, (ii) cardiovascular complications of kidney disease, and (iii) cardiovascular disease in the general population. As a physician, his interest in clinical trials stems from the relevance and immediate applicability of trial results to patient care. He has led major meta-analyses clarifying the effects of a range of interventions in patients with kidney disease and in the general population, which have consolidated and challenged prevailing practices in nephrology and are informing the development of new guidelines. Professor Perkovic led the development of George Clinical, the George Institute’s clinical trial arm and has built strong relationships with international clinical trial groups, including in China and throughout Asia. He is using these relationships to conduct key ‘public good’ trials. He is member of The Asian Forum of Chronic Kidney Disease Initiative, established to facilitate collaboration in chronic kidney disease research in the Asia-Pacific region. Professor Perkovic is a member of the International Society of Nephrology’s Advisory Committee for Clinical Trials. He chairs the Scientific Committee of the Australasian Kidney Trials Network and is a member of the NHMRC Academy and the Heart Foundation BP guidelines group.

Research interests

Professor Perkovic leads and conducts national and international clinical trials and meta-analyses relating to preventing and treating (a) kidney disease, (b) its complications and (c) cardiovascular disease in the general population. Trials on preventing kidney disease and its progression include TESTING, a global study of 1300 patients with IgA nephropathy randomised to oral steroids or placebo, and the subsequent risk of ESKD, and adverse outcomes. He chairs the Steering Committee for CREDENCE, a global 3700-person trial aiming to define whether canagliflozin prevents kidney failure in diabetic nephropathy, and he serves on the Steering Committees of the SONAR (atrasentan in diabetic nephropathy) trial. Professor Perkovic led analyses of the ADVANCE trial that have highlighted the importance of kidney function and albuminuria as risk factors for kidney failure and cardiovascular disease, and the benefits of glucose control in the kidney.

Trials aimed at improving outcomes for patients with kidney disease include SHARP, where Professor Perkovic and team helped recruit/manage over a quarter of the 9,455 patients. He leads the ACTIVE Dialysis trial comparing extended hours to standard dialysis in patients with ESKD. The BLOCADE trial will assess the effects of routine beta blockade on mortality and CV outcomes in patients with dialysis-dependent kidney failure. He led data analyses that have contributed significantly to the understanding of managing CV risk in people with kidney disease, including the effectiveness of blood pressure lowering and of aspirin in CKD. He has conducted systematic reviews defining the effects of a range of interventions on CV outcomes in CKD.

He contributes to studies defining strategies for preventing cardiovascular disease in the general population, including CANVAS (which evaluates a new class of glucose-lowering agents (SGLT2 inhibitors) on CV outcomes in people with diabetes), and CARMELINA (an 8300-patient trial of the efficacy and CV and renal safety of linagliptin in type 2 diabetes).

Selected grants

2014

  • Discovery and translation of evidence for new strategies to combat cardiovascular diseases; MacMahon S, Chalmers J, Neal B, Woodward M, Anderson C, Patel A, Rodgers A, Perkovic V; National Health and Medical Research Council (NHMRC)/Program Grants.
  • Senior Research Fellowship B - Growing the evidence base for improved outcomes in chronic kidney disease; Perkovic V; National Health and Medical Research Council (NHMRC)/Career Awards: Research Fellowships.

2013

  • The SIGNAL Trial: Steroids in ImmunoGlobulin A Nephropathy: Assessment of Long term outcomes; Perkovic V, Wang H, Cass A, Jha V, Levin A, Feehally J, Johnson D; National Health and Medical Research Council (NHMRC)/Project Grants.

2011

  • The BLOCADE trial; Mathews R, Hawley C, Perkovic V, Kerr P, Pollock C; National Health and Medical Research Council (NHMRC)/Project Grants.

2010

  • Preventing the cardiovscular complication of kidney disease; Perkovic V; National Heart Foundation/Career Development Fellowship.
  • NSW Cardiovascular Research Network and Heart Foundation Career Development Award; Perkovic V; Heart Foundation of Australia/Career Development Fellowship.
  • Enabling Grant Australasian Kidney Trials Network; Perkovic V; Australasian Kidney Trials Network/Enabling Grant.
  • ADVANCE Biomarker Study; Perkovic V, Hillis G, Thomas M; National Health and Medical Research Council (NHMRC)/Project Grants.
  • Utility of novel biomarkers in the prediction of major complications of type II diabetes mellitus; Perkovic V, Hillis G, Thomas M, Lowe G; National Health and Medical Research Council (NHMRC)/Project Grants.

2009

  • Erythropoiesis Stimulating Agents Trialists Collaboration ; Cass A, Baigent C, Perkovic V, Huxley R, Baigent C, Levin A; National Health and Medical Research Council (NHMRC)/Project Grants.
  • ACTIVE Dialysis: a clinical trial of intensive dialysis; Cass A, Kerr P, Perkovic V, Howard K, AGAR J, Hawley C, Kerr P; National Health and Medical Research Council (NHMRC)/Project Grants.
  • The effect of glucose control and glucose lowering therapies in chronic kidney disease; Perkovic V; Diabetes Australia Research Trust (DART)/Research Grants.
  • ACTIVE dialysis-a Clinical Trial of intensive dialysis; Cass A, Perkovic V, Howard K, Agar J, Hawley C, Kerr P; National Health and Medical Research Council (NHMRC)/Project Grants.
  • The PEXIVAS Trial; Peh C, Hawley C, Perkovic V, Kerr P; National Health and Medical Research Council (NHMRC)/Project Grants.
  • The Erythropoietin Stimulating Agent Trialists Collaboration; Cass A, Perkovic V, Huxley R, Baigent C, Levin A; National Health and Medical Research Council (NHMRC)/Project Grants.

2008

  • Blood pressure lowering in patients with chronic kidney disease: evidence from prospectively planned overview analyses; Turnbull F, Barzi F, Perkovic V; National Health and Medical Research Council (NHMRC)/Project Grants.
  • Blood Pressure Lowering and Kidney Disease; Turnbull F, Perkovic V, Barzi F; National Health and Medical Research Council (NHMRC)/Project Grants.

2007

  • Kidney disease as a cardiovascular risk factor-defining its magnitude and therapeutic options; Perkovic V; National Heart Foundation/Postdoctoral Research Fellowship.
  • Not known; Woodward M, Huxley R, Neal B, Barzi F, Perkovic V; Unilever Australasia/Research Contract.

2006

  • Unknown; MacMahon S, Huxley R, Turnbull F, Perkovic V; Pfizer/Research Grant.

Selected publications

Download citations: PDF RTF Endnote

Books

  • Chalmers, J., Colagiuri, S., Cooper, M., Grobbee, R., Hamet, P., Kengne, A., MacMahon, S., Marre, M., Mogensen, C., Neal, B., Patel, A., Perkovic, V., et al (2008). Prevention of vascular outcomes in type 2 diabetes: benefits of intensive blood pressure and blood glucose control with Preterax and Diamicron MR. France: Wolters Kluwer Health France.

Edited Books

  • Chalmers, J., Colagiuri, S., Grobbee, R., Hamet, P., Kengne, A., MacMahon, S., Mogensen, C., Neal, B., Patel, A., Perkovic, V., et al (2007). New approaches for the prevention of vascular disease in type 2 diabetes: benefits of blood pressure lowering with the fixed combination of perindopril and indapamide. France: Wolters Kluwer Health Pharma Solutions.

Book Chapters

  • Wang, A., Jardine, M., Perkovic, V. (2014). Kidney Disease in Diabetes. In D. John Betteridge, Stephen Nicholls (Eds.), Managing Cardiovascular Complications in Diabetes, (pp. 58-86). Chichester: John Wiley & Sons.
  • Chalmers, J., Cooper, M., Grobbee, R., Hamet, P., Kengne, A., MacMahon, S., Marre, M., Mogensen, C., Neal, B., Patel, A., et al (2010). Protection against cardiovascular and renal disease in type 2 diabetes: ADVANCEs in the control of blood pressure Peterax and Diamicron MR. In J Chalmers (Eds.), Action in Diabetes and Vascular Disease: Preterax and Diamicron Mr Controlled Evaluation. France: Wolters Kluwer Health France.
  • Perkovic, V., Jardine, M., Gallagher, M., Cass, A. (2009). Lipid lowering in chronic kidney disease. In A.M. Tonkin (Eds.), Therapeutic Strategies in Lipid Disorders, (pp. 135-142). United Kingdom: Clinical Publishing, Oxford.
  • Perkovic, V., Ninomiya, T., MacMahon, S., Chalmers, J. (2009). Renal and microalbuminuria data from ADVANCE. In Bernard I. Levy, Harry A.J. Struijker-Boudier (Eds.), Role of Macro and Microcirculation in Target Organ Damage in Diabetes and Hypertension, (pp. 121-132). West Sussex: Wiley-Blackwell Publishing.

Journals

  • Johnson, D., Pascoe, E., Badve, S., Dalziel, K., Cass, A., Clarke, P., Ferrari, P., McDonald, S., Morrish, A., Pedagogos, E., Perkovic, V., et al (2015). A Randomized, Placebo-Controlled Trial of Pentoxifylline on Erythropoiesis-Stimulating Agent Hyporesponsiveness in Anemic Patients With CKD: The Handling Erythropoietin Resistance With Oxpentifylline (HERO) Trial. American Journal of Kidney Diseases, 65(1), 49-57. [More Information]
  • Emdin, C., Rahimi, K., Neal, B., Callender, T., Perkovic, V., Patel, A. (2015). Blood pressure lowering in type 2 diabetes : A systematic review and meta-analysis. JAMA: The Journal of the American Medical Association, 313(6), 603-615. [More Information]
  • Zhu, B., Zhu, C., Lin, Y., Perkovic, V., Li, X., Yang, R., Tang, X., Zhu, X., Cheng, X., Li, Q., et al (2015). Clinical characteristics of IgA nephropathy associated with low complement 4 levels. Renal Failure, 37(3), 424-432. [More Information]
  • Laba, T., Usherwood, T., Leeder, S., Yusuf, F., Gillespie, J., Perkovic, V., Wilson, A., Jan, S., Essue, B. (2015). Co-payments for health care: what is their real cost? Australian Health Review, 39(1), 33-36. [More Information]
  • Jardine, M., Zuo, L., Gray, N., de Zoysa, J., Chan, C., Gallagher, M., Howard, K., Heritier, S., Cass, A., Perkovic, V. (2015). Design and participant baseline characteristics of 'A Clinical Trial of IntensiVE Dialysis' - the ACTIVE Dialysis Study. Nephrology, 20(4), 257-265. [More Information]
  • Neal, B., Perkovic, V., de Zeeuw, D., Mahaffey, K., Fulcher, G., Ways, K., Desai, M., Shaw, W., Capuano, G., Alba, M., et al (2015). Efficacy and Safety of Canagliflozin, an Inhibitor of Sodium Glucose Cotransporter 2, When Used in Conjunction With Insulin Therapy in Patients With Type 2 Diabetes. Diabetes Care, 38(3), 403-411. [More Information]
  • Jun, M., James, M., Manns, B., Quinn, R., Ravani, P., Tonelli, M., Perkovic, V., Winkelmayer, W., Ma, Z., Hemmelgarn, B. (2015). The association between kidney function and major bleeding in older adults with atrial fibrillation starting warfarin treatment: population based observational study. BMJ, 350, 1-9. [More Information]
  • Roberts, M., Pilmore, H., Ierino, F., Badve, S., Cass, A., Garg, A., Hawley, C., Isbel, N., Krum, H., Pascoe, E., Perkovic, V., et al (2015). The rationale and design of the Beta-blocker to LOwer CArdiovascular Dialysis Events (BLOCADE) Feasibility Study. Nephrology, 20(3), 140-147. [More Information]
  • Liyanage, T., Ninomiya, T., Jha, V., Neal, B., Patrice, H., Okpechi, I., Zhao, M., Lv, J., Garg, A., Knight, J., Rodgers, A., Gallagher, M., Kotwal, S., Cass, A., Perkovic, V. (2015). Worldwide access to treatment for end stage kidney disease: a systematic review. The Lancet, 385, 1975-1982. [More Information]
  • Liyanage, T., Ninomiya, T., Jha, V., Neal, B., Patrice, H., Okpechi, I., Zhao, M., Lv, J., Garg, A., Knight, J., Rodgers, A., Gallagher, M., Kotwal, S., Cass, A., Perkovic, V. (2015). Worldwide access to treatment for end-stage kidney disease: a systematic review. The Lancet, 385(9981), 1975-1182. [More Information]
  • Ninomiya, T., Perkovic, V. (2014). Authors' reply to Ladapo and Ogedegbe. BMJ, 348, 1-1. [More Information]
  • Sundström, J., Arima, H., Woodward, M., Jackson, R., Karmali, K., Lloyd-Jones, D., Baigent, C., Emberson, J., Rahimi, K., MacMahon, S., Patel, A., Perkovic, V., Neal, B., et al (2014). Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data. The Lancet, 384(9943), 591-598. [More Information]
  • Pilmore, H., Dogra, G., Roberts, M., Lambers Heerspink, H., Ninomiya, T., Huxley, R., Perkovic, V. (2014). Cardiovascular disease in patients with chronic kidney disease. Nephrology, 19(1), 3-10. [More Information]
  • Wang, A., Ninomiya, T., Al-Kahwa, A., Perkovic, V., Gallagher, M., Hawley, C., Jardine, M. (2014). Effect of Hemodiafiltration or Hemofiltration Compared With Hemodialysis on Mortality and Cardiovascular Disease in Chronic Kidney Failure: A Systematic Review and Meta-analysis of Randomized Trials. American Journal of Kidney Diseases, 63(6), 968-978. [More Information]
  • Bose, B., Badve, S., Hiremath, S., Boudville, N., Brown, F., Cass, A., de Zoysa, J., Fassett, R., Faull, R., Harris, D., Perkovic, V., Rangan, G., et al (2014). Effects of uric acid-lowering therapy on renal outcomes: a systematic review and meta-analysis. Nephrology, Dialysis, Transplantation, 29(2), 406-413. [More Information]
  • Yamout, H., Perkovic, V., Davies, M., Woo, V., de Zeeuw, D., Mayer, C., Vijapurkar, U., Kline, I., Usiskin, K., Meininger, G., et al (2014). Efficacy and safety of canagliflozin in patients with type 2 diabetes and stage 3 nephropathy. American Journal of Nephrology, 40(1), 64-74. [More Information]
  • Morrish, A., Hawley, C., Johnson, D., Badve, S., Perkovic, V., Reidlinger, D., Cass, A. (2014). Establishing a clinical trials network in nephrology: Experience of the Australasian Kidney Trials Network. Kidney International, 85(1), 23-30. [More Information]
  • Zoungas, S., Chalmers, J., Neal, B., Billot, L., Li, Q., Hirakawa, Y., Arima, H., Monaghan, H., Joshi, R., Colagiuri, S., Perkovic, V., Rodgers, A., MacMahon, S., Patel, A., Woodward, M., et al (2014). Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. The New England Journal of Medicine, 371(15), 1392-1406. [More Information]
  • Palmer, S., Navaneethan, S., Craig, J., Perkovic, V., Johnson, D., Nigwekar, S., Hegbrant, J., Strippoli, G. (2014). HMG CoA reductase inhibitors (statins) for kidney transplant recipients. Cochrane Database of Systematic Reviews, 2014 (1), 1-57. [More Information]
  • Palmer, S., Navaneethan, S., Craig, J., Johnson, D., Perkovic, V., Hegbrant, J., Strippoli, G. (2014). HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database of Systematic Reviews, 5, 1-136. [More Information]
  • Perkovic, V., Turnbull, F., Wilson, A. (2014). Is it time for Medi-change? Medical Journal of Australia, 200(10), 566-567. [More Information]
  • Knight, J., Wong, M., Perkovic, V. (2014). Optimal targets for blood pressure control in chronic kidney disease: the debate continues. Current Opinion In Nephrology And Hypertension, 23(6), 541-546. [More Information]
  • de Zeeuw, D., Coll, B., Andress, D., Brennan, J., Tang, H., Houser, M., Correa-Rotter, R., Kohan, D., Lambers Heerspink, H., Makino, H., Perkovic, V., et al (2014). The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy. Journal of the American Society of Nephrology, 25(5), 1083-1093. [More Information]
  • Huxley, R., Perkovic, V. (2014). The modifiable burden of worldwide mortality from cardiovascular diseases. The Lancet Diabetes & Endocrinology, 2(8), 604-606. [More Information]
  • Hillis, G., Welsh, P., Chalmers, J., Perkovic, V., Chow, C., Li, Q., Jun, M., Neal, B., Zoungas, S., Poulter, N., Woodward, M., et al (2014). The relative and combined ability of high sensitivity cardiac troponin T and N-terminal pro-B-type Natriuretic Peptide to predict cardiovascular events and death in patients with type 2 diabetes. Diabetes Care, 37(1), 295-303. [More Information]
  • Sindone, A., Erlich, J., Perkovic, V., Suranyi, M., Newman, H., Lee, C., Barin, E., Roger, S. (2013). ACEIs for cardiovascular risk reduction: Have we taken our eye off the ball? Australian Family Physician, 42(9), 634-638. [More Information]
  • Wang, A., Ivany, J., Perkovic, V., Gallagher, M., Jardine, M. (2013). Anticoagulant therapies for the prevention of intravascular catheters malfunction in patients undergoing haemodialysis: systematic review and meta-analysis of randomized, controlled trials. Nephrology, Dialysis, Transplantation, 28(11), 2875-2888. [More Information]
  • Palmer, S., Di Micco, L., Razavian, M., Craig, J., Perkovic, V., Pellegrini, F., Jardine, M., Webster, A., Zoungas, S., Strippoli, G., et al (2013). Antiplatelet agents for chronic kidney disease. Cochrane Database of Systematic Reviews, 2013 (4), 1-136. [More Information]
  • Palmer, S., Di Micco, L., Razavian, M., Craig, J., Ravani, P., Perkovic, V., Tognoni, G., Graziano, G., Jardine, M., Pellegrini, F., Webster, A., Strippoli, G., et al (2013). Antiplatelet Therapy to Prevent Hemodialysis Vascular Access Failure: Systematic Review and Meta-analysis. American Journal of Kidney Diseases, 61(1), 112-122. [More Information]
  • Ninomiya, T., Perkovic, V., Turnbull, F., Neal, B., Barzi, F., Cass, A., Baigent, C., Chalmers, J., Li, N., Woodward, M., MacMahon, S. (2013). Blood pressure lowering and major cardiovascular events in people with and without chronic kidney disease: meta-analysis of randomised controlled trials. BMJ, 347(7929), 1-15. [More Information]
  • Wong, M., Perkovic, V., Woodward, M., Chalmers, J., Li, Q., Hillis, G., Azari, E., Jun, M., Poulter, N., Hamet, P., Neal, B., Pollock, C., et al (2013). Circulating bone morphogenetic protein-7 and transforming growth factor-(beta)1 are better predictors of renal end points in patients with type 2 diabetes mellitus. Kidney International, 83(2), 278-284. [More Information]
  • Wang, A., Ivany, J., Perkovic, V., Gallagher, M., Jardine, M. (2013). Corrigendum: Anticoagulant therapies for the prevention of intravascular catheters malfunction in patients undergoing haemodialysis: systematic review and meta-analysis of randomized, controlled trials. Nephrology, Dialysis, Transplantation, 28, 3127-3127.
  • Hou, W., Lv, J., Perkovic, V., Yang, L., Zhao, N., Jardine, M., Cass, A., Zhang, H., Wang, H. (2013). Effect of statin therapy on cardiovascular and renal outcomes in patients with chronic kidney disease: a systematic review and meta-analysis. European Heart Journal, 34(24), 1807-1817. [More Information]
  • Lv, J., Ehteshami, P., Sarnak, M., Tighiouart, H., Jun, M., Ninomiya, T., Foote, C., Rodgers, A., Zhang, H., Wang, H., Strippoli, G., Perkovic, V. (2013). Effects of intensive blood pressure lowering on the progression of chronic kidney disease: a systematic review and meta-analysis. CMAJ - Canadian Medical Association Journal, 185(11), 949-957. [More Information]
  • Levin, A., Perkovic, V. (2013). Epidemiology: Global Burden of Disease Study 2010: implications for nephrology. Nature Reviews Nephrology, 9(4), 195-197. [More Information]
  • Perkovic, V., Neuen, B., Taylor, G., Demaio, A. (2013). Global kidney disease. The Lancet, 382(9900), 1243.
  • Palmer, S., Navaneethan, S., Craig, J., Johnson, D., Perkovic, V., Nigwekar, S., Hegbrant, J., Strippoli, G. (2013). HMG CoA reductase inhibitors (statins) for dialysis patients. Cochrane Database of Systematic Reviews, 2013 (9), 1-81. [More Information]
  • MacMahon, S., Perkovic, V., Patel, A. (2013). Industry-sponsored clinical trials in emerging markets: time to review the terms of engagement. JAMA, 310(9), 907-908. [More Information]
  • Perkovic, V., Heerspink, H., Chalmers, J., Woodward, M., Jun, M., Li, Q., MacMahon, S., Cooper, M., Hamet, P., Marre, M., Cass, A., Patel, A., Zoungas, S., et al (2013). Intensive glucose control improves kidney outcomes in patients with type 2 diabetes. Kidney International, 83(3), 517-523. [More Information]
  • Badve, S., Beller, E., Cass, A., Francis, D., Hawley, C., Macdougall, I., Perkovic, V., Johnson, D. (2013). Interventions for erythropoietin-resistant anaemia in dialysis patients. Cochrane Database of Systematic Reviews, 2013 (8), 1-37. [More Information]
  • Groop, P., Cooper, M., Perkovic, V., Emser, A., Woerle, H., von Eynatten, M. (2013). Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction. Diabetes Care, 36(11), 3460-3468. [More Information]
  • Jardine, M., Liyanage, T., Buxton, E., Perkovic, V. (2013). mTOR inhibition in autosomal-dominant polycystic kidney disease (ADPKD): the question remains open. Nephrology, Dialysis, Transplantation, 28(2), 242-244. [More Information]
  • Jun, M., Jardine, M., Gray, N., Masterson, R., Kerr, P., Agar, J., Hawley, C., van Eps, C., Cass, A., Gallagher, M., Perkovic, V. (2013). Outcomes of Extended-Hours Hemodialysis Performed Predominantly at Home. American Journal of Kidney Diseases, 61(2), 247-253. [More Information]
  • Mooney, J., Ranasinghe, I., Chow, C., Perkovic, V., Barzi, F., Zoungas, S., Holzmann, M., Welten, G., Biancari, F., Wu, V., Cass, A., Hillis, G., et al (2013). Preoperative Estimates of Glomerular Filtration Rate as Predictors of Outcome after Surgery: A Systematic Review and Meta-analysis. Anesthesiology, 118(4), 809-824. [More Information]
  • Neal, B., Perkovic, V., de Zeeuw, D., Mahaffey, K., Fulcher, G., Stein, P., Desai, M., Shaw, W., Jiang, J., Vercruysse, F., et al (2013). Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)-A randomized placebo-controlled trial. American Heart Journal, 166(2), 217-223. [More Information]
  • Perkovic, V., Woodward, M., Zoungas, S., Chalmers, J. (2013). The authors reply Caution advised in interpreting nonsignificant results from ADVANCE post hoc analysis. Kidney International, 84(3), 622-622. [More Information]
  • Zhu, B., Wang, Y., Jardine, M., Jun, M., Lv, J., Cass, A., Liyanage, T., Cheng, H., Wang, Y., Perkovic, V. (2013). Tripterygium Preparations for the Treatment of CKD: A Systematic Review and Meta-analysis. American Journal of Kidney Diseases, 62(3), 515-530. [More Information]
  • Wang, Y., Ivany, J., Perkovic, V., Gallagher, M., Jardine, M. (2012). Anticoagulants and antiplatelet agents for preventing central venous haemodialysis catheter malfunction in patients with end-stage kidney disease. Cochrane Database of Systematic Reviews, 2012 (2), 1-11. [More Information]
  • Lv, J., Perkovic, V., Foote, C., Craig, M., Craig, J., Strippoli, G. (2012). Antihypertensive agents for preventing diabetic kidney disease (Review). Cochrane Database of Systematic Reviews, (12), 1-90. [More Information]
  • Jun, M., Venkataraman, V., Razavian, M., Cooper, B., Zoungas, S., Ninomiya, T., Webster, A., Perkovic, V. (2012). Antioxidants for chronic kidney disease (Review). Cochrane Database of Systematic Reviews, 10, 1-61. [More Information]
  • Razavian, M., Heeley, E., Perkovic, V., Zoungas, S., Weekes, A., Patel, A., Anderson, C., Chalmers, J., Cass, A. (2012). Cardiovascular risk management in chronic kidney disease in general practice (the AusHEART study). Nephrology, Dialysis, Transplantation, 27(4), 1396-1402. [More Information]
  • Lv, J., Xu, D., Perkovic, V., Ma, X., Johnson, D., Woodward, M., Levin, A., Zhang, H., Wang, H. (2012). Corticosteroid Therapy in IgA Nephropathy. Journal of the American Society of Nephrology, 23(6), 1108-1116. [More Information]
  • Palmer, S., Di Micco, L., Razavian, M., Craig, J., Perkovic, V., Pellegrini, F., Copetti, M., Graziano, G., Tognoni, G., Jardine, M., Webster, A., Strippoli, G., et al (2012). Effects of Antiplatelet Therapy on Mortality and Cardiovascular and Bleeding Outcomes in Persons With Chronic Kidney Disease: A Systematic Review and Meta-analysis. Annals of Internal Medicine, 156(6), 445-459. [More Information]
  • Jun, M., Zhu, B., Tonelli, M., Jardine, M., Patel, A., Neal, B., Liyanage, T., Keech, A., Cass, A., Perkovic, V. (2012). Effects of Fibrates in Kidney Disease: A Systematic Review and Meta-Analysis. Journal of the American College of Cardiology, 60(20), 2061-2071. [More Information]
  • Lv, J., Neal, B., Ehteshami, P., Ninomiya, T., Woodward, M., Rodgers, A., Wang, H., MacMahon, S., Turnbull, F., Hillis, G., Chalmers, J., Perkovic, V. (2012). Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: a systematic review and meta-analysis. PLoS Medicine, 9(8), 1-14. [More Information]
  • Foote, C., Perkovic, V., Neal, B. (2012). Effects of SGLT2 inhibitors on cardiovascular outcomes. Diabetes and Vascular Disease Research, 9(2), 117-123. [More Information]
  • Perkovic, V., Patil, V., Wei, L., Lv, J., Petersen, M., Patel, A. (2012). Global Randomized Trials: The Promise of India and China. Journal of Bone and Joint Surgery: American Volume, 94(Suppl 1(E)), 92-96. [More Information]
  • Jun, M., Lo, C., Badve, S., Pilmore, H., White, S., Hawley, C., Cass, A., Perkovic, V., Zoungas, S. (2012). Glucose lowering therapies for chronic kidney disease and kidney transplantation (Protocol). Cochrane Database of Systematic Reviews, 2012 (8), 1-13. [More Information]
  • Zhu, B., Jun, M., Jardine, M., Wang, Y., Perkovic, V. (2012). Haemodialysis duration, frequency and intensity for end-stage kidney disease (Protocol). Cochrane Database of Systematic Reviews, 2012 (9), 1-10. [More Information]
  • Becker, G., Wheeler, D., de Zeeuw, D., Fujita, T., Furth, S., Holdaas, H., Mendis, S., Oparil, S., Perkovic, V., Rodrigues, C., et al (2012). KDIGO Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney International Supplements, 2(5), 337-414. [More Information]
  • Kotwal, S., Jun, M., Sullivan, D., Perkovic, V., Neal, B. (2012). Omega 3 Fatty Acids and Cardiovascular Outcomes: Systematic Review and Meta-Analysis. Circulation. Cardiovascular Quality and Outcomes, 5(6), 808-818. [More Information]
  • Toussaint, N., Pedagogos, E., Tan, S., Badve, S., Hawley, C., Perkovic, V., Elder, G. (2012). Phosphate in early chronic kidney disease: Associations with clinical outcomes and a target to reduce cardiovascular risk. Nephrology, 17(5), 433-444. [More Information]
  • Jardine, M., Hata, J., Woodward, M., Perkovic, V., Ninomiya, T., Arima, H., Zoungas, S., Cass, A., Patel, A., Marre, M., Chalmers, J., et al (2012). Prediction of Kidney-Related Outcomes in Patients With Type 2 Diabetes. American Journal of Kidney Diseases, 60(5), 770-778. [More Information]
  • Hillis, G., Hata, J., Woodward, M., Perkovic, V., Arima, H., Chow, C., Zoungas, S., Patel, A., Poulter, N., Mancia, G., Chalmers, J., et al (2012). Resting Heart Rate and the Risk of Microvascular Complications in Patients With Type 2 Diabetes Mellitus. Journal of the American Heart Association, 1(5), 1-11. [More Information]
  • Foote, C., Ninomiya, T., Gallagher, M., Perkovic, V., Cass, A., McDonald, S., Jardine, M. (2012). Survival of elderly dialysis patients is predicted by both patient and practice characteristics. Nephrology, Dialysis, Transplantation, 27, 3581-3587. [More Information]
  • Jardine, M., Kang, A., Zoungas, S., Navaneethan, S., Ninomiya, T., Nigwekar, S., Gallagher, M., Cass, A., Strippoli, G., Perkovic, V. (2012). The effect of folic acid based homocysteine lowering on cardiovascular events in people with kidney disease: systematic review and meta-analysis. BMJ, 344(7863), 1-11. [More Information]
  • Wong, G., Zoungas, S., Lo, S., Chalmers, J., Cass, A., Neal, B., Woodward, M., Perkovic, V., Glasziou, P., Williams, B., Howard, K., Chapman, J., Craig, J. (2012). The risk of cancer in people with diabetes and chronic kidney disease. Nephrology, Dialysis, Transplantation, 27(8), 3337-3344. [More Information]
  • Perkovic, V., Neal, B. (2012). Trials in Kidney Disease - Time to EVOLVE. The New England Journal of Medicine, 367(26), 2541-2542. [More Information]
  • Maione, A., Navaneethan, S., Graziano, G., Mitchell, R., Johnson, D., Mann, J., Gao, P., Craig, J., Tognoni, G., Perkovic, V., Strippoli, G., et al (2011). Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and combined therapy in patients with micro- and macroalbuminuria and other cardiovascular risk factors: a systematic review of randomized controlled trials. Nephrology, Dialysis, Transplantation, 26(9), 2827-2847. [More Information]
  • Lv, J., Perkovic, V. (2011). Blood pressure management in diabetes: a path forward? Journal of Hypertension, 29(7), 1283-1284. [More Information]
  • Badve, S., Brown, F., Hawley, C., Johnson, D., Kanellis, J., Rangan, G., Perkovic, V. (2011). Challenges of conducting a trial of uric-acid-lowering therapy in CKD. Nature Reviews Nephrology, 7(5), 295-300. [More Information]
  • Badve, S., Roberts, M., Hawley, C., Cass, A., Garg, A., Krum, H., Tonkin, A., Perkovic, V. (2011). Effects of Beta-adrenergic antagonists in patients with chronic kidney disease a systematic review and meta-analysis. Journal of the American College of Cardiology, 58(11), 1152-1161. [More Information]
  • Jun, M., Perkovic, V., Cass, A. (2011). Intensive Glycemic Control and Renal Outcome. Contributions to Nephrology, 170, 196-208. [More Information]
  • Komala, M., Pianta, T., Jardine, M., Webster, A., Perkovic, V. (2011). Interventions for preventing intradialytic hypotension inhaemodialysis patients (Protocol). Cochrane Database of Systematic Reviews, (12), 1-12. [More Information]
  • Heerspink, H., Perkovic, V., de Zeeuw, D. (2011). Is doubling of serum creatinine a valid clinical 'hard' endpoint in clinical nephrology trials? Nephron Clinical Practice, 119(3), c195-c199. [More Information]
  • Huxley, R., Barzi, F., Lam, T., Czernichow, S., Fang, X., Welborn, T., Shaw, J., Ueshima, H., Zimmet, P., Jee, S., Caterson, I., Perkovic, V., Woodward, M., et al (2011). Isolated Low Levels of High-Density Lipoprotein Cholesterol Are Associated With an Increased Risk of Coronary Heart Disease: An Individual Participant Data Meta-Analysis of 23 Studies in the Asia-Pacific Region. Circulation, 124(19), 2056-2064. [More Information]
  • Perkovic, V., Jun, M., Lv, J., Jardine, M. (2011). Managing cardiovascular risk in people with chronic kidney disease: a review of the evidence from randomized controlled trials. Therapeutic Advances in Chronic Diseases, 2(4), 265-278. [More Information]
  • Perkovic, V., Huxley, R. (2011). Prognostic value of CRP in stable coronary artery disease unclear due to a variety of biases in existing studies, therefore no clinical practice recommendations can be made. Advances in Colloid and Interface Science, 167(1-2), 94-103. [More Information]
  • Zentner, D., Hunt, D., Chan, W., Barzi, F., Grigg, L., Perkovic, V. (2011). Prospective evaluation of aortic stenosis in end-stage kidney disease: a more fulminant process? Nephrology, Dialysis, Transplantation, 26(5), 1651-1655. [More Information]
  • Czernichow, S., Zanchetti, A., Turnbull, F., Barzi, F., Ninomiya, T., Kengne, A., Heerspink, H., Perkovic, V., Huxley, R., Arima, H., Patel, A., Chalmers, J., Woodward, M., MacMahon, S., Neal, B. (2011). The effects of blood pressure reduction and of different blood pressure-lowering regimens on major cardiovascular events according to baseline blood pressure: meta-analysis of randomized trials. Journal of Hypertension, 29(1), 4-16. [More Information]
  • Tsukamoto, Y., Jha, V., Becker, G., Chen, H., Perkovic, V., Prodjosudjadi, W., Tungsanga, K., Wang, H., Morad, Z. (2010). A challenge to chronic kidney disease in Asia: The report of the second Asian Forum of Chronic Kidney Disease Initiative. Nephrology, 15(2), 248-252. [More Information]
  • Razavian, M., Di Micco, L., Palmer, S., Craig, J., Perkovic, V., Zoungas, S., Webster, A., Jardine, M., Strippoli, G. (2010). Antiplatelet agents for chronic kidney disease (Protocol). Cochrane Database of Systematic Reviews, 2010 (11), 1-16. [More Information]
  • Jardine, M., Ninomiya, T., Perkovic, V., Cass, A., Turnbull, F., Gallagher, M., Zoungas, S., Heerspink, H., Chalmers, J., Zanchetti, A. (2010). Aspirin is beneficial in hypertensive patients with chronic kidney disease a post-hoc subgroup analysis of a randomized controlled trial. Journal of the American College of Cardiology, 56(12), 956-965. [More Information]
  • Lambers Heerspink, H., Ninomiya, T., Perkovic, V., Woodward, M., Zoungas, S., Cass, A., Cooper, M., Grobbee, D., Mancia, G., Mogensen, C., Neal, B., Chalmers, J. (2010). Effects of a fixed combination of perindopril and indapamide in patients with type 2 diabetes and chronic kidney disease. European Heart Journal, 31(23), 2888-2896. [More Information]
  • Perkovic, V., Jun, M., Neal, B. (2010). Effects of fibrates on cardiovascular outcomes - Authors' reply. The Lancet, 376(9746), 1051-1052. [More Information]
  • Neal, B., Jun, M., Foote, C., Lv, J., Patel, A., Nicholls, S., Grobbee, D., Cass, A., Chalmers, J., Perkovic, V. (2010). Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. The Lancet, 375(9729), 1875-1884. [More Information]
  • Ninomiya, T., Zoungas, S., Neal, B., Woodward, M., Patel, A., Perkovic, V., Cass, A., Cooper, M., Grobbee, D., Hamet, P., Rodgers, A., MacMahon, S., Chalmers, J., et al (2010). Efficacy and safety of routine blood pressure lowering in older patients with diabetes: results from the ADVANCE trial. Journal of Hypertension, 28(6), 1141-1149. [More Information]
  • Perkovic, V., Cass, A. (2010). Glomerular filtration rate and the risk of stroke. BMJ (online), 341, c4390. [More Information]
  • Jun, M., Zoungas, S., Perkovic, V., Webster, A. (2010). How to read a report of a randomized controlled trial. Nephrology, 15(2), 153-157. [More Information]
  • Jun, M., Lambers Heerspink, H., Ninomiya, T., Gallagher, M., Bellomo, R., Myburgh, J., Finfer, S., Palevsky, P., Kellum, J., Perkovic, V., Cass, A. (2010). Intensities of Renal Replacement Therapy in Acute Kidney Injury: A Systematic Review and Meta-Analysis. Clinical Journal of the American Society of Nephrology, 5(6), 956-963. [More Information]
  • Badve, S., Beller, E., Cass, A., Francis, D., Hawley, C., Macdougall, I., Perkovic, V., Johnson, D. (2010). Interventions for erythropoietin-resistant anaemia in dialysis patients (Protocol). Cochrane Database of Systematic Reviews, 2010 (1), 1-10. [More Information]
  • Gallagher, M., Kelly, P., Jardine, M., Perkovic, V., Cass, A., Craig, J., Eris, J., Webster, A. (2010). Long-Term Cancer Risk of Immunosuppressive Regimens after Kidney Transplantation. Journal of the American Society of Nephrology, 21(5), 852-858. [More Information]
  • Palmer, S., Navaneethan, S., Craig, J., Johnson, D., Tonelli, M., Garg, A., Pellegrini, F., Ravani, P., Jardine, M., Perkovic, V., Strippoli, G., et al (2010). Meta-analysis: Erythropoiesis-Stimulating Agents in Patients With Chronic Kidney Disease. Annals of Internal Medicine, 153(1), 23-34. [More Information]
  • Ninomiya, T., Perkovic, V., de Galan, B., Zoungas, S., Pillai, A., Jardine, M., Patel, A., Cass, A., Neal, B., Poulter, N., Woodward, M., MacMahon, S., Chalmers, J., et al (2009). Albuminuria and Kidney Function Independently Predict Cardiovascular and Renal Outcomes in Diabetes. Journal of the American Society of Nephrology, 20(8), 1813-1821. [More Information]
  • Perkovic, V., Venkataraman, V., Cooper, B., Zoungas, S., Webster, A. (2009). Antioxidants for chronic kidney disease (Protocol). Cochrane Database of Systematic Reviews, 2009 (4), 1-12. [More Information]
  • O'Seaghdha, C., Perkovic, V., Lam, T., McGinn, S., Barzi, F., Gu, D., Cass, A., Suh, I., Muntner, P., Giles, G., Woodward, M., Huxley, R., et al (2009). Blood Pressure Is a Major Risk Factor for Renal Death. An Analysis of 560 352 Participants From the Asia-Pacific Region. Hypertension, 54(3), 509-515. [More Information]
  • Perkovic, V., Heerspink, H., Ninomiya, T., Cass, A., Neal, B. (2009). Blood pressure lowering in dialysis patients - look before we leap. The Lancet, 373, 1945-1946.
  • Huxley, R., Lee, C., Barzi, F., Timmermeister, L., Czernichow, S., Perkovic, V., Grobbee, D., Batty, G., Woodward, M. (2009). Coffee, decaffeinated coffee, and tea consumption in relation to incident type 2 diabetes mellitus: A systematic review with meta-analysis. Archives of Internal Medicine, 169(22), 2053-2063. [More Information]
  • Gallagher, M., Jardine, M., Perkovic, V., Cass, A., McDonald, S., Petrie, J., Eris, J. (2009). Cyclosporine withdrawal improves long-term graft survival in renal transplantation. Transplantation, 87(12), 1877-1883. [More Information]
  • Lambers Heerspink, H., Ninomiya, T., Zoungas, S., de Zeeuw, D., Grobbee, D., Jardine, M., Gallagher, M., Roberts, M., Cass, A., Neal, B., Perkovic, V. (2009). Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials. The Lancet, 373(9668), 1009-1015. [More Information]
  • Hu, J., Jiang, X., Li, N., Yu, X., Perkovic, V., Chen, B., Zhao, L., Neal, B., Wu, Y. (2009). Effects of salt substitute on pulse wave analysis among individuals at high cardiovascular risk in rural China: a randomized controlled trial. Hypertension Research, 32(4), 282-288. [More Information]
  • Navaneethan, S., Nigwekar, S., Perkovic, V., Johnson, D., Craig, J., Strippoli, G. (2009). HMG CoA reductase inhibitors (statins) for dialysis patients (Review). Cochrane Database of Systematic Reviews, (3), 1-39. [More Information]
  • Navaneethan, S., Perkovic, V., Johnson, D., Nigwekar, S., Craig, J., Strippoli, G. (2009). HMG CoA reductase inhibitors (statins) for kidney transplant recipients. Cochrane Database of Systematic Reviews, (2), 1-30. [More Information]
  • Navaneethan, S., Pansini, F., Perkovic, V., Manno, C., Pellegrini, F., Johnson, D., Craig, J., Strippoli, G. (2009). HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database of Systematic Reviews, (2), 1-48. [More Information]
  • Huxley, R., Clifton, P., Perkovic, V., Woodward, M., Neal, B. (2009). How many Australian deaths from heart disease and stroke could be avoided by a small reduction in population cholesterol levels? Nutrition and Dietetics, 66(3), 158-163. [More Information]
  • Nigwekar, S., Cass, A., Gallagher, M., Jardine, M., Kang, A., Kulshrestha, S., Navaneethan, S., Perkovic, V., Strippoli, G., Zoungas, S. (2009). Interventions for lowering plasma homocysteine levels in dialysis patients. Cochrane Database of Systematic Reviews, 2, 1-12. [More Information]
  • Kang, A., Nigwekar, S., Perkovic, V., Kulshrestha, S., Zoungas, S., Navaneethan, S., Cass, A., Gallagher, M., Ninomiya, T., Strippoli, G., et al (2009). Interventions for lowering plasma homocysteine levels in kidney transplant recipients [Protocol]. Cochrane Database of Systematic Reviews, (3), 1-12. [More Information]
  • White, S., Perkovic, V., Cass, A., Chang, C., Poulter, N., Spector, T., Haysom, L., Craig, J., Al Salmi, I., Chadban, S., Huxley, R. (2009). Is Low Birth Weight an Antecedent of CKD in Later Life? A Systematic Review of Observational Studies. American Journal of Kidney Diseases, 54(2), 248-261. [More Information]
  • de Galan, B., Perkovic, V., Ninomiya, T., Pillai, A., Patel, A., Cass, A., Neal, B., Poulter, N., Harrap, S., Mogensen, C., Woodward, M., MacMahon, S., Chalmers, J., et al (2009). Lowering Blood Pressure Reduces Renal Events in Type 2 Diabetes. Journal of the American Society of Nephrology, 20(4), 883-892. [More Information]
  • Ninomiya, T., Perkovic, V., Verdon, C., Barzi, F., Cass, A., Gallagher, M., Jardine, M., Anderson, C., Chalmers, J., Craig, J., Huxley, R. (2009). Proteinuria and Stroke: A Meta-analysis of Cohort Studies. American Journal of Kidney Diseases, 53(3), 417-425. [More Information]
  • Lambers Heerspink, H., Perkovic, V., de Zeeuw, D. (2009). Renal and cardio-protective effects of direct renin inhibition: a systematic literature review. Journal of Hypertension, 27(12), 2321-2331. [More Information]
  • Joshi, R., de Galan, B., Chalmers, J., Perkovic, V., Patel, A. (2009). Routine blood pressure lowering and intense glucose control in patients with type 2 diabetes: results from the ADVANCE trial. Expert Review of Endocrinology & Metabolism, 4(2), 111-118.
  • Zoungas, S., Ninomiya, T., Huxley, R., Cass, A., Jardine, M., Gallagher, M., Patel, A., Vasheghani-Farahani, A., Sadigh, G., Perkovic, V. (2009). Systematic review: sodium bicarbonate treatment regimens for the prevention of contrast-induced nephropathy. Annals of Internal Medicine, 151(9), 631-638. [More Information]
  • Turnbull, F., Woodward, M., Neal, B., Barzi, F., Ninomiya, T., Chalmers, J., Perkovic, V., Li, N., MacMahon, S. (2008). Do men and women respond differently to blood pressure-lowering treatment? Results of prospectively designed overviews of randomized trials. European Heart Journal, 29(21), 2669-2680. [More Information]
  • Turnbull, F., Neal, B., Ninomiya, T., Algert, C., Arima, H., Barzi, F., Bulpitt, C., Chalmers, J., Fagard, R., Gleason, A., Heritier, S., Perkovic, V., Woodward, M., MacMahon, S., et al (2008). Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ: British Medical Journal, 336(6753), 1121-1123. [More Information]
  • Strippoli, G., Navaneethan, S., Perkovic, V., Pellegrini, F., Nicolucci, A., Johnson, D., Craig, J. (2008). Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials. BMJ: British Medical Journal, 336(7645), 1-14. [More Information]
  • Perkovic, V., Cass, A., Patel, A., Suriyawongpaisal, P., Barzi, F., Chadban, S., MacMahon, S., Neal, B. (2008). High prevalence of chronic kidney disease in Thailand. Kidney International, 73(4), 473-479. [More Information]
  • Patel, A., MacMahon, S., Chalmers, J., Neal, B., Billot, L., Woodward, M., Marre, M., Cooper, M., Glasziou, P., Grobbee, D., Joshi, R., et al (2008). Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. New England Journal of Medicine, 358(24), 2560-2572. [More Information]
  • Ninomiya, T., Perkovic, V., Gallagher, M., Jardine, M., Cass, A., Arima, H., Anderson, C., Neal, B., Woodward, M., Omae, T., MacMahon, S., Chalmers, J. (2008). Lower blood pressure and risk of recurrent stroke in patients with chronic kidney disease: PROGRESS trial. Kidney International, 73(8), 963-970. [More Information]
  • White, S., McGeechan, K., Jones, M., Cass, A., Chadban, S., Polkinghorne, K., Perkovic, V., Roderick, P. (2008). Socioeconomic Disadvantage and Kidney Disease in the United States, Australia, and Thailand. American Journal of Public Health, 98(7), 1306-1313. [More Information]
  • Perkovic, V., Verdon, C., Ninomiya, T., Barzi, F., Cass, A., Patel, A., Jardine, M., Gallagher, M., Turnbull, F., Chalmers, J., Craig, J., Huxley, R. (2008). The relationship between proteinuria and coronary risk: a systematic review and meta-analysis. PLoS Medicine, 5(10), 1486-1495. [More Information]
  • Perkovic, V., Ninomiya, T., Arima, H., Jardine, M., Cass, A., Neal, B., MacMahon, S., Chalmers, J. (2007). Chronic Kidney Disease, Cardiovascular Events, and The Effects Of Perindopril-Based Blood Pressure Lowering: Data From The PROGRESS Study. Journal of the American Society of Nephrology, 18(10), 2766-2772. [More Information]
  • Chalmers, J., Kengne, A., Joshi, R., Perkovic, V., Patel, A. (2007). New insights from ADVANCE. Journal of Hypertension, 25(Suppl. 1), S23-S30. [More Information]
  • Chalmers, J., Perkovic, V., Joshi, R., Patel, A. (2006). ADVANCE: breaking new ground in type 2 diabetes. Journal of Hypertension, 24(Supplement 5), S22-S28. [More Information]
  • Perkovic, V., Joshi, R., Patel, A., Bompoint, S., Chalmers, J., Neal, B., MacMahon, S., Glasziou, P., Woodward, M., Cooper, M., et al (2006). ADVANCE: Lessons from the run-in phase of a large study in type 2 diabetes. Blood Pressure, 15(6), 340-346. [More Information]
  • Gallagher, M., Perkovic, V., Chalmers, J. (2006). Diuretics: A modern day treatment option? (Review Article). Nephrology, 11(5), 419-427. [More Information]
  • Kerr, P., Perkovic, V., Petrie, J., Agar, J., Disney, A. (2005). Dose of haemodialysis. Nephrology, 10, S61-3. [More Information]
  • Perkovic, V., Hewitson, T., Kelynack, K., Martic, M., Tait, M., Becker, G. (2003). Parathyroid hormone has a prosclerotic effect on vascular smooth muscle cells. Kidney and Blood Pressure Research, 26(1), 27-33. [More Information]

Conferences

  • Perkovic, V. (2011). Blood pressure lowering in CKD. 4th European Meeting on Uraemia and Cardiovascular Disease, Not-Known.
  • Perkovic, V. (2011). Overview of clinical trials in acute Kidney Injury. World Congress of Nephrology 2011, Not-Known: International Society of Nephrology.
  • Perkovic, V. (2011). Thrice weekly Hemodialysis is obsolete and should not be offered as standard treatment for ESRD. World Congress of Nephrology 2011, Not-Known: International Society of Nephrology.
  • Perkovic, V. (2010). Optimal Blood Pressure Target and Agents in Hemodialysis Patients? 42nd Annual Meeting of the Canadian Society of Nephrology, Not-Known.
  • Perkovic, V. (2008). Anaemia management and EBM: What have we learned? Australian Clinical Nephrology Symposium 2008, Not-Known.
  • Craig, J., Perkovic, V., Chadban, S., Cass, A., McDonald, S., Salkeld, G., Howard, K., White, S. (2008). Cost effectiveness of screening for the early diagnosis and treatment of risk factors for chronic kidney disease: a Markov Monte Carlo microsimulation using marck-E (model for the assessment of risk factors for chronic kidney disease - economics). 42nd Australia and New Zealand Society of Nephrology Annual Scientific Conference (2006), United States of America: Wiley-Blackwell Publishing.
  • Perkovic, V. (2008). Diabetes, Kidney Disease and Cardiovascular disease workshop. AstraZeneca Cardiovascular Specialist Symposium 2008, Not-Known.
  • Perkovic, V. (2008). Specific Consideration in etiology and risk factor of ESKD in Asia. 2nd Meeting of the Asian forum of CDK Initiative, Not-Known.
  • Howard, K., Salkeld, G., White, S., Chadban, S., Craig, J., Cass, A., McDonald, S., Perkovic, V. (2006). Cost effectiveness of screening for the early diagnosis and treatment of risk factors for chronic kidney disease: A Markov Monte Carlo microsimulation using Marck-E. 42nd Annual Scientific Meeting of the Australian and New Zealand Society of Nephrology.

Report

  • Howard, K., Salkeld, G., White, S., Chadban, S., Craig, J., McDonald, S., Perkovic, V., Cass, A. (2006). The cost-effectiveness of early detection and intervention to prevent the progression of Chronic Kidney Disease in Australia.
  • Howard, K., Salkeld, G., White, S., Chadban, S., Craig, J., McDonald, S., Perkovic, V., Cass, A. (2006). The Cost-Effectiveness of Early Detection and Intervention to Prevent the Progression of Chronic Kidney Disease in Australia.

2015

  • Johnson, D., Pascoe, E., Badve, S., Dalziel, K., Cass, A., Clarke, P., Ferrari, P., McDonald, S., Morrish, A., Pedagogos, E., Perkovic, V., et al (2015). A Randomized, Placebo-Controlled Trial of Pentoxifylline on Erythropoiesis-Stimulating Agent Hyporesponsiveness in Anemic Patients With CKD: The Handling Erythropoietin Resistance With Oxpentifylline (HERO) Trial. American Journal of Kidney Diseases, 65(1), 49-57. [More Information]
  • Emdin, C., Rahimi, K., Neal, B., Callender, T., Perkovic, V., Patel, A. (2015). Blood pressure lowering in type 2 diabetes : A systematic review and meta-analysis. JAMA: The Journal of the American Medical Association, 313(6), 603-615. [More Information]
  • Zhu, B., Zhu, C., Lin, Y., Perkovic, V., Li, X., Yang, R., Tang, X., Zhu, X., Cheng, X., Li, Q., et al (2015). Clinical characteristics of IgA nephropathy associated with low complement 4 levels. Renal Failure, 37(3), 424-432. [More Information]
  • Laba, T., Usherwood, T., Leeder, S., Yusuf, F., Gillespie, J., Perkovic, V., Wilson, A., Jan, S., Essue, B. (2015). Co-payments for health care: what is their real cost? Australian Health Review, 39(1), 33-36. [More Information]
  • Jardine, M., Zuo, L., Gray, N., de Zoysa, J., Chan, C., Gallagher, M., Howard, K., Heritier, S., Cass, A., Perkovic, V. (2015). Design and participant baseline characteristics of 'A Clinical Trial of IntensiVE Dialysis' - the ACTIVE Dialysis Study. Nephrology, 20(4), 257-265. [More Information]
  • Neal, B., Perkovic, V., de Zeeuw, D., Mahaffey, K., Fulcher, G., Ways, K., Desai, M., Shaw, W., Capuano, G., Alba, M., et al (2015). Efficacy and Safety of Canagliflozin, an Inhibitor of Sodium Glucose Cotransporter 2, When Used in Conjunction With Insulin Therapy in Patients With Type 2 Diabetes. Diabetes Care, 38(3), 403-411. [More Information]
  • Jun, M., James, M., Manns, B., Quinn, R., Ravani, P., Tonelli, M., Perkovic, V., Winkelmayer, W., Ma, Z., Hemmelgarn, B. (2015). The association between kidney function and major bleeding in older adults with atrial fibrillation starting warfarin treatment: population based observational study. BMJ, 350, 1-9. [More Information]
  • Roberts, M., Pilmore, H., Ierino, F., Badve, S., Cass, A., Garg, A., Hawley, C., Isbel, N., Krum, H., Pascoe, E., Perkovic, V., et al (2015). The rationale and design of the Beta-blocker to LOwer CArdiovascular Dialysis Events (BLOCADE) Feasibility Study. Nephrology, 20(3), 140-147. [More Information]
  • Liyanage, T., Ninomiya, T., Jha, V., Neal, B., Patrice, H., Okpechi, I., Zhao, M., Lv, J., Garg, A., Knight, J., Rodgers, A., Gallagher, M., Kotwal, S., Cass, A., Perkovic, V. (2015). Worldwide access to treatment for end stage kidney disease: a systematic review. The Lancet, 385, 1975-1982. [More Information]
  • Liyanage, T., Ninomiya, T., Jha, V., Neal, B., Patrice, H., Okpechi, I., Zhao, M., Lv, J., Garg, A., Knight, J., Rodgers, A., Gallagher, M., Kotwal, S., Cass, A., Perkovic, V. (2015). Worldwide access to treatment for end-stage kidney disease: a systematic review. The Lancet, 385(9981), 1975-1182. [More Information]

2014

  • Ninomiya, T., Perkovic, V. (2014). Authors' reply to Ladapo and Ogedegbe. BMJ, 348, 1-1. [More Information]
  • Sundström, J., Arima, H., Woodward, M., Jackson, R., Karmali, K., Lloyd-Jones, D., Baigent, C., Emberson, J., Rahimi, K., MacMahon, S., Patel, A., Perkovic, V., Neal, B., et al (2014). Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data. The Lancet, 384(9943), 591-598. [More Information]
  • Pilmore, H., Dogra, G., Roberts, M., Lambers Heerspink, H., Ninomiya, T., Huxley, R., Perkovic, V. (2014). Cardiovascular disease in patients with chronic kidney disease. Nephrology, 19(1), 3-10. [More Information]
  • Wang, A., Ninomiya, T., Al-Kahwa, A., Perkovic, V., Gallagher, M., Hawley, C., Jardine, M. (2014). Effect of Hemodiafiltration or Hemofiltration Compared With Hemodialysis on Mortality and Cardiovascular Disease in Chronic Kidney Failure: A Systematic Review and Meta-analysis of Randomized Trials. American Journal of Kidney Diseases, 63(6), 968-978. [More Information]
  • Bose, B., Badve, S., Hiremath, S., Boudville, N., Brown, F., Cass, A., de Zoysa, J., Fassett, R., Faull, R., Harris, D., Perkovic, V., Rangan, G., et al (2014). Effects of uric acid-lowering therapy on renal outcomes: a systematic review and meta-analysis. Nephrology, Dialysis, Transplantation, 29(2), 406-413. [More Information]
  • Yamout, H., Perkovic, V., Davies, M., Woo, V., de Zeeuw, D., Mayer, C., Vijapurkar, U., Kline, I., Usiskin, K., Meininger, G., et al (2014). Efficacy and safety of canagliflozin in patients with type 2 diabetes and stage 3 nephropathy. American Journal of Nephrology, 40(1), 64-74. [More Information]
  • Morrish, A., Hawley, C., Johnson, D., Badve, S., Perkovic, V., Reidlinger, D., Cass, A. (2014). Establishing a clinical trials network in nephrology: Experience of the Australasian Kidney Trials Network. Kidney International, 85(1), 23-30. [More Information]
  • Zoungas, S., Chalmers, J., Neal, B., Billot, L., Li, Q., Hirakawa, Y., Arima, H., Monaghan, H., Joshi, R., Colagiuri, S., Perkovic, V., Rodgers, A., MacMahon, S., Patel, A., Woodward, M., et al (2014). Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. The New England Journal of Medicine, 371(15), 1392-1406. [More Information]
  • Palmer, S., Navaneethan, S., Craig, J., Perkovic, V., Johnson, D., Nigwekar, S., Hegbrant, J., Strippoli, G. (2014). HMG CoA reductase inhibitors (statins) for kidney transplant recipients. Cochrane Database of Systematic Reviews, 2014 (1), 1-57. [More Information]
  • Palmer, S., Navaneethan, S., Craig, J., Johnson, D., Perkovic, V., Hegbrant, J., Strippoli, G. (2014). HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database of Systematic Reviews, 5, 1-136. [More Information]
  • Perkovic, V., Turnbull, F., Wilson, A. (2014). Is it time for Medi-change? Medical Journal of Australia, 200(10), 566-567. [More Information]
  • Wang, A., Jardine, M., Perkovic, V. (2014). Kidney Disease in Diabetes. In D. John Betteridge, Stephen Nicholls (Eds.), Managing Cardiovascular Complications in Diabetes, (pp. 58-86). Chichester: John Wiley & Sons.
  • Knight, J., Wong, M., Perkovic, V. (2014). Optimal targets for blood pressure control in chronic kidney disease: the debate continues. Current Opinion In Nephrology And Hypertension, 23(6), 541-546. [More Information]
  • de Zeeuw, D., Coll, B., Andress, D., Brennan, J., Tang, H., Houser, M., Correa-Rotter, R., Kohan, D., Lambers Heerspink, H., Makino, H., Perkovic, V., et al (2014). The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy. Journal of the American Society of Nephrology, 25(5), 1083-1093. [More Information]
  • Huxley, R., Perkovic, V. (2014). The modifiable burden of worldwide mortality from cardiovascular diseases. The Lancet Diabetes & Endocrinology, 2(8), 604-606. [More Information]
  • Hillis, G., Welsh, P., Chalmers, J., Perkovic, V., Chow, C., Li, Q., Jun, M., Neal, B., Zoungas, S., Poulter, N., Woodward, M., et al (2014). The relative and combined ability of high sensitivity cardiac troponin T and N-terminal pro-B-type Natriuretic Peptide to predict cardiovascular events and death in patients with type 2 diabetes. Diabetes Care, 37(1), 295-303. [More Information]

2013

  • Sindone, A., Erlich, J., Perkovic, V., Suranyi, M., Newman, H., Lee, C., Barin, E., Roger, S. (2013). ACEIs for cardiovascular risk reduction: Have we taken our eye off the ball? Australian Family Physician, 42(9), 634-638. [More Information]
  • Wang, A., Ivany, J., Perkovic, V., Gallagher, M., Jardine, M. (2013). Anticoagulant therapies for the prevention of intravascular catheters malfunction in patients undergoing haemodialysis: systematic review and meta-analysis of randomized, controlled trials. Nephrology, Dialysis, Transplantation, 28(11), 2875-2888. [More Information]
  • Palmer, S., Di Micco, L., Razavian, M., Craig, J., Perkovic, V., Pellegrini, F., Jardine, M., Webster, A., Zoungas, S., Strippoli, G., et al (2013). Antiplatelet agents for chronic kidney disease. Cochrane Database of Systematic Reviews, 2013 (4), 1-136. [More Information]
  • Palmer, S., Di Micco, L., Razavian, M., Craig, J., Ravani, P., Perkovic, V., Tognoni, G., Graziano, G., Jardine, M., Pellegrini, F., Webster, A., Strippoli, G., et al (2013). Antiplatelet Therapy to Prevent Hemodialysis Vascular Access Failure: Systematic Review and Meta-analysis. American Journal of Kidney Diseases, 61(1), 112-122. [More Information]
  • Ninomiya, T., Perkovic, V., Turnbull, F., Neal, B., Barzi, F., Cass, A., Baigent, C., Chalmers, J., Li, N., Woodward, M., MacMahon, S. (2013). Blood pressure lowering and major cardiovascular events in people with and without chronic kidney disease: meta-analysis of randomised controlled trials. BMJ, 347(7929), 1-15. [More Information]
  • Wong, M., Perkovic, V., Woodward, M., Chalmers, J., Li, Q., Hillis, G., Azari, E., Jun, M., Poulter, N., Hamet, P., Neal, B., Pollock, C., et al (2013). Circulating bone morphogenetic protein-7 and transforming growth factor-(beta)1 are better predictors of renal end points in patients with type 2 diabetes mellitus. Kidney International, 83(2), 278-284. [More Information]
  • Wang, A., Ivany, J., Perkovic, V., Gallagher, M., Jardine, M. (2013). Corrigendum: Anticoagulant therapies for the prevention of intravascular catheters malfunction in patients undergoing haemodialysis: systematic review and meta-analysis of randomized, controlled trials. Nephrology, Dialysis, Transplantation, 28, 3127-3127.
  • Hou, W., Lv, J., Perkovic, V., Yang, L., Zhao, N., Jardine, M., Cass, A., Zhang, H., Wang, H. (2013). Effect of statin therapy on cardiovascular and renal outcomes in patients with chronic kidney disease: a systematic review and meta-analysis. European Heart Journal, 34(24), 1807-1817. [More Information]
  • Lv, J., Ehteshami, P., Sarnak, M., Tighiouart, H., Jun, M., Ninomiya, T., Foote, C., Rodgers, A., Zhang, H., Wang, H., Strippoli, G., Perkovic, V. (2013). Effects of intensive blood pressure lowering on the progression of chronic kidney disease: a systematic review and meta-analysis. CMAJ - Canadian Medical Association Journal, 185(11), 949-957. [More Information]
  • Levin, A., Perkovic, V. (2013). Epidemiology: Global Burden of Disease Study 2010: implications for nephrology. Nature Reviews Nephrology, 9(4), 195-197. [More Information]
  • Perkovic, V., Neuen, B., Taylor, G., Demaio, A. (2013). Global kidney disease. The Lancet, 382(9900), 1243.
  • Palmer, S., Navaneethan, S., Craig, J., Johnson, D., Perkovic, V., Nigwekar, S., Hegbrant, J., Strippoli, G. (2013). HMG CoA reductase inhibitors (statins) for dialysis patients. Cochrane Database of Systematic Reviews, 2013 (9), 1-81. [More Information]
  • MacMahon, S., Perkovic, V., Patel, A. (2013). Industry-sponsored clinical trials in emerging markets: time to review the terms of engagement. JAMA, 310(9), 907-908. [More Information]
  • Perkovic, V., Heerspink, H., Chalmers, J., Woodward, M., Jun, M., Li, Q., MacMahon, S., Cooper, M., Hamet, P., Marre, M., Cass, A., Patel, A., Zoungas, S., et al (2013). Intensive glucose control improves kidney outcomes in patients with type 2 diabetes. Kidney International, 83(3), 517-523. [More Information]
  • Badve, S., Beller, E., Cass, A., Francis, D., Hawley, C., Macdougall, I., Perkovic, V., Johnson, D. (2013). Interventions for erythropoietin-resistant anaemia in dialysis patients. Cochrane Database of Systematic Reviews, 2013 (8), 1-37. [More Information]
  • Groop, P., Cooper, M., Perkovic, V., Emser, A., Woerle, H., von Eynatten, M. (2013). Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction. Diabetes Care, 36(11), 3460-3468. [More Information]
  • Jardine, M., Liyanage, T., Buxton, E., Perkovic, V. (2013). mTOR inhibition in autosomal-dominant polycystic kidney disease (ADPKD): the question remains open. Nephrology, Dialysis, Transplantation, 28(2), 242-244. [More Information]
  • Jun, M., Jardine, M., Gray, N., Masterson, R., Kerr, P., Agar, J., Hawley, C., van Eps, C., Cass, A., Gallagher, M., Perkovic, V. (2013). Outcomes of Extended-Hours Hemodialysis Performed Predominantly at Home. American Journal of Kidney Diseases, 61(2), 247-253. [More Information]
  • Mooney, J., Ranasinghe, I., Chow, C., Perkovic, V., Barzi, F., Zoungas, S., Holzmann, M., Welten, G., Biancari, F., Wu, V., Cass, A., Hillis, G., et al (2013). Preoperative Estimates of Glomerular Filtration Rate as Predictors of Outcome after Surgery: A Systematic Review and Meta-analysis. Anesthesiology, 118(4), 809-824. [More Information]
  • Neal, B., Perkovic, V., de Zeeuw, D., Mahaffey, K., Fulcher, G., Stein, P., Desai, M., Shaw, W., Jiang, J., Vercruysse, F., et al (2013). Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)-A randomized placebo-controlled trial. American Heart Journal, 166(2), 217-223. [More Information]
  • Perkovic, V., Woodward, M., Zoungas, S., Chalmers, J. (2013). The authors reply Caution advised in interpreting nonsignificant results from ADVANCE post hoc analysis. Kidney International, 84(3), 622-622. [More Information]
  • Zhu, B., Wang, Y., Jardine, M., Jun, M., Lv, J., Cass, A., Liyanage, T., Cheng, H., Wang, Y., Perkovic, V. (2013). Tripterygium Preparations for the Treatment of CKD: A Systematic Review and Meta-analysis. American Journal of Kidney Diseases, 62(3), 515-530. [More Information]

2012

  • Wang, Y., Ivany, J., Perkovic, V., Gallagher, M., Jardine, M. (2012). Anticoagulants and antiplatelet agents for preventing central venous haemodialysis catheter malfunction in patients with end-stage kidney disease. Cochrane Database of Systematic Reviews, 2012 (2), 1-11. [More Information]
  • Lv, J., Perkovic, V., Foote, C., Craig, M., Craig, J., Strippoli, G. (2012). Antihypertensive agents for preventing diabetic kidney disease (Review). Cochrane Database of Systematic Reviews, (12), 1-90. [More Information]
  • Jun, M., Venkataraman, V., Razavian, M., Cooper, B., Zoungas, S., Ninomiya, T., Webster, A., Perkovic, V. (2012). Antioxidants for chronic kidney disease (Review). Cochrane Database of Systematic Reviews, 10, 1-61. [More Information]
  • Razavian, M., Heeley, E., Perkovic, V., Zoungas, S., Weekes, A., Patel, A., Anderson, C., Chalmers, J., Cass, A. (2012). Cardiovascular risk management in chronic kidney disease in general practice (the AusHEART study). Nephrology, Dialysis, Transplantation, 27(4), 1396-1402. [More Information]
  • Lv, J., Xu, D., Perkovic, V., Ma, X., Johnson, D., Woodward, M., Levin, A., Zhang, H., Wang, H. (2012). Corticosteroid Therapy in IgA Nephropathy. Journal of the American Society of Nephrology, 23(6), 1108-1116. [More Information]
  • Palmer, S., Di Micco, L., Razavian, M., Craig, J., Perkovic, V., Pellegrini, F., Copetti, M., Graziano, G., Tognoni, G., Jardine, M., Webster, A., Strippoli, G., et al (2012). Effects of Antiplatelet Therapy on Mortality and Cardiovascular and Bleeding Outcomes in Persons With Chronic Kidney Disease: A Systematic Review and Meta-analysis. Annals of Internal Medicine, 156(6), 445-459. [More Information]
  • Jun, M., Zhu, B., Tonelli, M., Jardine, M., Patel, A., Neal, B., Liyanage, T., Keech, A., Cass, A., Perkovic, V. (2012). Effects of Fibrates in Kidney Disease: A Systematic Review and Meta-Analysis. Journal of the American College of Cardiology, 60(20), 2061-2071. [More Information]
  • Lv, J., Neal, B., Ehteshami, P., Ninomiya, T., Woodward, M., Rodgers, A., Wang, H., MacMahon, S., Turnbull, F., Hillis, G., Chalmers, J., Perkovic, V. (2012). Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: a systematic review and meta-analysis. PLoS Medicine, 9(8), 1-14. [More Information]
  • Foote, C., Perkovic, V., Neal, B. (2012). Effects of SGLT2 inhibitors on cardiovascular outcomes. Diabetes and Vascular Disease Research, 9(2), 117-123. [More Information]
  • Perkovic, V., Patil, V., Wei, L., Lv, J., Petersen, M., Patel, A. (2012). Global Randomized Trials: The Promise of India and China. Journal of Bone and Joint Surgery: American Volume, 94(Suppl 1(E)), 92-96. [More Information]
  • Jun, M., Lo, C., Badve, S., Pilmore, H., White, S., Hawley, C., Cass, A., Perkovic, V., Zoungas, S. (2012). Glucose lowering therapies for chronic kidney disease and kidney transplantation (Protocol). Cochrane Database of Systematic Reviews, 2012 (8), 1-13. [More Information]
  • Zhu, B., Jun, M., Jardine, M., Wang, Y., Perkovic, V. (2012). Haemodialysis duration, frequency and intensity for end-stage kidney disease (Protocol). Cochrane Database of Systematic Reviews, 2012 (9), 1-10. [More Information]
  • Becker, G., Wheeler, D., de Zeeuw, D., Fujita, T., Furth, S., Holdaas, H., Mendis, S., Oparil, S., Perkovic, V., Rodrigues, C., et al (2012). KDIGO Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney International Supplements, 2(5), 337-414. [More Information]
  • Kotwal, S., Jun, M., Sullivan, D., Perkovic, V., Neal, B. (2012). Omega 3 Fatty Acids and Cardiovascular Outcomes: Systematic Review and Meta-Analysis. Circulation. Cardiovascular Quality and Outcomes, 5(6), 808-818. [More Information]
  • Toussaint, N., Pedagogos, E., Tan, S., Badve, S., Hawley, C., Perkovic, V., Elder, G. (2012). Phosphate in early chronic kidney disease: Associations with clinical outcomes and a target to reduce cardiovascular risk. Nephrology, 17(5), 433-444. [More Information]
  • Jardine, M., Hata, J., Woodward, M., Perkovic, V., Ninomiya, T., Arima, H., Zoungas, S., Cass, A., Patel, A., Marre, M., Chalmers, J., et al (2012). Prediction of Kidney-Related Outcomes in Patients With Type 2 Diabetes. American Journal of Kidney Diseases, 60(5), 770-778. [More Information]
  • Hillis, G., Hata, J., Woodward, M., Perkovic, V., Arima, H., Chow, C., Zoungas, S., Patel, A., Poulter, N., Mancia, G., Chalmers, J., et al (2012). Resting Heart Rate and the Risk of Microvascular Complications in Patients With Type 2 Diabetes Mellitus. Journal of the American Heart Association, 1(5), 1-11. [More Information]
  • Foote, C., Ninomiya, T., Gallagher, M., Perkovic, V., Cass, A., McDonald, S., Jardine, M. (2012). Survival of elderly dialysis patients is predicted by both patient and practice characteristics. Nephrology, Dialysis, Transplantation, 27, 3581-3587. [More Information]
  • Jardine, M., Kang, A., Zoungas, S., Navaneethan, S., Ninomiya, T., Nigwekar, S., Gallagher, M., Cass, A., Strippoli, G., Perkovic, V. (2012). The effect of folic acid based homocysteine lowering on cardiovascular events in people with kidney disease: systematic review and meta-analysis. BMJ, 344(7863), 1-11. [More Information]
  • Wong, G., Zoungas, S., Lo, S., Chalmers, J., Cass, A., Neal, B., Woodward, M., Perkovic, V., Glasziou, P., Williams, B., Howard, K., Chapman, J., Craig, J. (2012). The risk of cancer in people with diabetes and chronic kidney disease. Nephrology, Dialysis, Transplantation, 27(8), 3337-3344. [More Information]
  • Perkovic, V., Neal, B. (2012). Trials in Kidney Disease - Time to EVOLVE. The New England Journal of Medicine, 367(26), 2541-2542. [More Information]

2011

  • Maione, A., Navaneethan, S., Graziano, G., Mitchell, R., Johnson, D., Mann, J., Gao, P., Craig, J., Tognoni, G., Perkovic, V., Strippoli, G., et al (2011). Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and combined therapy in patients with micro- and macroalbuminuria and other cardiovascular risk factors: a systematic review of randomized controlled trials. Nephrology, Dialysis, Transplantation, 26(9), 2827-2847. [More Information]
  • Perkovic, V. (2011). Blood pressure lowering in CKD. 4th European Meeting on Uraemia and Cardiovascular Disease, Not-Known.
  • Lv, J., Perkovic, V. (2011). Blood pressure management in diabetes: a path forward? Journal of Hypertension, 29(7), 1283-1284. [More Information]
  • Badve, S., Brown, F., Hawley, C., Johnson, D., Kanellis, J., Rangan, G., Perkovic, V. (2011). Challenges of conducting a trial of uric-acid-lowering therapy in CKD. Nature Reviews Nephrology, 7(5), 295-300. [More Information]
  • Badve, S., Roberts, M., Hawley, C., Cass, A., Garg, A., Krum, H., Tonkin, A., Perkovic, V. (2011). Effects of Beta-adrenergic antagonists in patients with chronic kidney disease a systematic review and meta-analysis. Journal of the American College of Cardiology, 58(11), 1152-1161. [More Information]
  • Jun, M., Perkovic, V., Cass, A. (2011). Intensive Glycemic Control and Renal Outcome. Contributions to Nephrology, 170, 196-208. [More Information]
  • Komala, M., Pianta, T., Jardine, M., Webster, A., Perkovic, V. (2011). Interventions for preventing intradialytic hypotension inhaemodialysis patients (Protocol). Cochrane Database of Systematic Reviews, (12), 1-12. [More Information]
  • Heerspink, H., Perkovic, V., de Zeeuw, D. (2011). Is doubling of serum creatinine a valid clinical 'hard' endpoint in clinical nephrology trials? Nephron Clinical Practice, 119(3), c195-c199. [More Information]
  • Huxley, R., Barzi, F., Lam, T., Czernichow, S., Fang, X., Welborn, T., Shaw, J., Ueshima, H., Zimmet, P., Jee, S., Caterson, I., Perkovic, V., Woodward, M., et al (2011). Isolated Low Levels of High-Density Lipoprotein Cholesterol Are Associated With an Increased Risk of Coronary Heart Disease: An Individual Participant Data Meta-Analysis of 23 Studies in the Asia-Pacific Region. Circulation, 124(19), 2056-2064. [More Information]
  • Perkovic, V., Jun, M., Lv, J., Jardine, M. (2011). Managing cardiovascular risk in people with chronic kidney disease: a review of the evidence from randomized controlled trials. Therapeutic Advances in Chronic Diseases, 2(4), 265-278. [More Information]
  • Perkovic, V. (2011). Overview of clinical trials in acute Kidney Injury. World Congress of Nephrology 2011, Not-Known: International Society of Nephrology.
  • Perkovic, V., Huxley, R. (2011). Prognostic value of CRP in stable coronary artery disease unclear due to a variety of biases in existing studies, therefore no clinical practice recommendations can be made. Advances in Colloid and Interface Science, 167(1-2), 94-103. [More Information]
  • Zentner, D., Hunt, D., Chan, W., Barzi, F., Grigg, L., Perkovic, V. (2011). Prospective evaluation of aortic stenosis in end-stage kidney disease: a more fulminant process? Nephrology, Dialysis, Transplantation, 26(5), 1651-1655. [More Information]
  • Czernichow, S., Zanchetti, A., Turnbull, F., Barzi, F., Ninomiya, T., Kengne, A., Heerspink, H., Perkovic, V., Huxley, R., Arima, H., Patel, A., Chalmers, J., Woodward, M., MacMahon, S., Neal, B. (2011). The effects of blood pressure reduction and of different blood pressure-lowering regimens on major cardiovascular events according to baseline blood pressure: meta-analysis of randomized trials. Journal of Hypertension, 29(1), 4-16. [More Information]
  • Perkovic, V. (2011). Thrice weekly Hemodialysis is obsolete and should not be offered as standard treatment for ESRD. World Congress of Nephrology 2011, Not-Known: International Society of Nephrology.

2010

  • Tsukamoto, Y., Jha, V., Becker, G., Chen, H., Perkovic, V., Prodjosudjadi, W., Tungsanga, K., Wang, H., Morad, Z. (2010). A challenge to chronic kidney disease in Asia: The report of the second Asian Forum of Chronic Kidney Disease Initiative. Nephrology, 15(2), 248-252. [More Information]
  • Razavian, M., Di Micco, L., Palmer, S., Craig, J., Perkovic, V., Zoungas, S., Webster, A., Jardine, M., Strippoli, G. (2010). Antiplatelet agents for chronic kidney disease (Protocol). Cochrane Database of Systematic Reviews, 2010 (11), 1-16. [More Information]
  • Jardine, M., Ninomiya, T., Perkovic, V., Cass, A., Turnbull, F., Gallagher, M., Zoungas, S., Heerspink, H., Chalmers, J., Zanchetti, A. (2010). Aspirin is beneficial in hypertensive patients with chronic kidney disease a post-hoc subgroup analysis of a randomized controlled trial. Journal of the American College of Cardiology, 56(12), 956-965. [More Information]
  • Lambers Heerspink, H., Ninomiya, T., Perkovic, V., Woodward, M., Zoungas, S., Cass, A., Cooper, M., Grobbee, D., Mancia, G., Mogensen, C., Neal, B., Chalmers, J. (2010). Effects of a fixed combination of perindopril and indapamide in patients with type 2 diabetes and chronic kidney disease. European Heart Journal, 31(23), 2888-2896. [More Information]
  • Perkovic, V., Jun, M., Neal, B. (2010). Effects of fibrates on cardiovascular outcomes - Authors' reply. The Lancet, 376(9746), 1051-1052. [More Information]
  • Neal, B., Jun, M., Foote, C., Lv, J., Patel, A., Nicholls, S., Grobbee, D., Cass, A., Chalmers, J., Perkovic, V. (2010). Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. The Lancet, 375(9729), 1875-1884. [More Information]
  • Ninomiya, T., Zoungas, S., Neal, B., Woodward, M., Patel, A., Perkovic, V., Cass, A., Cooper, M., Grobbee, D., Hamet, P., Rodgers, A., MacMahon, S., Chalmers, J., et al (2010). Efficacy and safety of routine blood pressure lowering in older patients with diabetes: results from the ADVANCE trial. Journal of Hypertension, 28(6), 1141-1149. [More Information]
  • Perkovic, V., Cass, A. (2010). Glomerular filtration rate and the risk of stroke. BMJ (online), 341, c4390. [More Information]
  • Jun, M., Zoungas, S., Perkovic, V., Webster, A. (2010). How to read a report of a randomized controlled trial. Nephrology, 15(2), 153-157. [More Information]
  • Jun, M., Lambers Heerspink, H., Ninomiya, T., Gallagher, M., Bellomo, R., Myburgh, J., Finfer, S., Palevsky, P., Kellum, J., Perkovic, V., Cass, A. (2010). Intensities of Renal Replacement Therapy in Acute Kidney Injury: A Systematic Review and Meta-Analysis. Clinical Journal of the American Society of Nephrology, 5(6), 956-963. [More Information]
  • Badve, S., Beller, E., Cass, A., Francis, D., Hawley, C., Macdougall, I., Perkovic, V., Johnson, D. (2010). Interventions for erythropoietin-resistant anaemia in dialysis patients (Protocol). Cochrane Database of Systematic Reviews, 2010 (1), 1-10. [More Information]
  • Gallagher, M., Kelly, P., Jardine, M., Perkovic, V., Cass, A., Craig, J., Eris, J., Webster, A. (2010). Long-Term Cancer Risk of Immunosuppressive Regimens after Kidney Transplantation. Journal of the American Society of Nephrology, 21(5), 852-858. [More Information]
  • Palmer, S., Navaneethan, S., Craig, J., Johnson, D., Tonelli, M., Garg, A., Pellegrini, F., Ravani, P., Jardine, M., Perkovic, V., Strippoli, G., et al (2010). Meta-analysis: Erythropoiesis-Stimulating Agents in Patients With Chronic Kidney Disease. Annals of Internal Medicine, 153(1), 23-34. [More Information]
  • Perkovic, V. (2010). Optimal Blood Pressure Target and Agents in Hemodialysis Patients? 42nd Annual Meeting of the Canadian Society of Nephrology, Not-Known.
  • Chalmers, J., Cooper, M., Grobbee, R., Hamet, P., Kengne, A., MacMahon, S., Marre, M., Mogensen, C., Neal, B., Patel, A., et al (2010). Protection against cardiovascular and renal disease in type 2 diabetes: ADVANCEs in the control of blood pressure Peterax and Diamicron MR. In J Chalmers (Eds.), Action in Diabetes and Vascular Disease: Preterax and Diamicron Mr Controlled Evaluation. France: Wolters Kluwer Health France.

2009

  • Ninomiya, T., Perkovic, V., de Galan, B., Zoungas, S., Pillai, A., Jardine, M., Patel, A., Cass, A., Neal, B., Poulter, N., Woodward, M., MacMahon, S., Chalmers, J., et al (2009). Albuminuria and Kidney Function Independently Predict Cardiovascular and Renal Outcomes in Diabetes. Journal of the American Society of Nephrology, 20(8), 1813-1821. [More Information]
  • Perkovic, V., Venkataraman, V., Cooper, B., Zoungas, S., Webster, A. (2009). Antioxidants for chronic kidney disease (Protocol). Cochrane Database of Systematic Reviews, 2009 (4), 1-12. [More Information]
  • O'Seaghdha, C., Perkovic, V., Lam, T., McGinn, S., Barzi, F., Gu, D., Cass, A., Suh, I., Muntner, P., Giles, G., Woodward, M., Huxley, R., et al (2009). Blood Pressure Is a Major Risk Factor for Renal Death. An Analysis of 560 352 Participants From the Asia-Pacific Region. Hypertension, 54(3), 509-515. [More Information]
  • Perkovic, V., Heerspink, H., Ninomiya, T., Cass, A., Neal, B. (2009). Blood pressure lowering in dialysis patients - look before we leap. The Lancet, 373, 1945-1946.
  • Huxley, R., Lee, C., Barzi, F., Timmermeister, L., Czernichow, S., Perkovic, V., Grobbee, D., Batty, G., Woodward, M. (2009). Coffee, decaffeinated coffee, and tea consumption in relation to incident type 2 diabetes mellitus: A systematic review with meta-analysis. Archives of Internal Medicine, 169(22), 2053-2063. [More Information]
  • Gallagher, M., Jardine, M., Perkovic, V., Cass, A., McDonald, S., Petrie, J., Eris, J. (2009). Cyclosporine withdrawal improves long-term graft survival in renal transplantation. Transplantation, 87(12), 1877-1883. [More Information]
  • Lambers Heerspink, H., Ninomiya, T., Zoungas, S., de Zeeuw, D., Grobbee, D., Jardine, M., Gallagher, M., Roberts, M., Cass, A., Neal, B., Perkovic, V. (2009). Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials. The Lancet, 373(9668), 1009-1015. [More Information]
  • Hu, J., Jiang, X., Li, N., Yu, X., Perkovic, V., Chen, B., Zhao, L., Neal, B., Wu, Y. (2009). Effects of salt substitute on pulse wave analysis among individuals at high cardiovascular risk in rural China: a randomized controlled trial. Hypertension Research, 32(4), 282-288. [More Information]
  • Navaneethan, S., Nigwekar, S., Perkovic, V., Johnson, D., Craig, J., Strippoli, G. (2009). HMG CoA reductase inhibitors (statins) for dialysis patients (Review). Cochrane Database of Systematic Reviews, (3), 1-39. [More Information]
  • Navaneethan, S., Perkovic, V., Johnson, D., Nigwekar, S., Craig, J., Strippoli, G. (2009). HMG CoA reductase inhibitors (statins) for kidney transplant recipients. Cochrane Database of Systematic Reviews, (2), 1-30. [More Information]
  • Navaneethan, S., Pansini, F., Perkovic, V., Manno, C., Pellegrini, F., Johnson, D., Craig, J., Strippoli, G. (2009). HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database of Systematic Reviews, (2), 1-48. [More Information]
  • Huxley, R., Clifton, P., Perkovic, V., Woodward, M., Neal, B. (2009). How many Australian deaths from heart disease and stroke could be avoided by a small reduction in population cholesterol levels? Nutrition and Dietetics, 66(3), 158-163. [More Information]
  • Nigwekar, S., Cass, A., Gallagher, M., Jardine, M., Kang, A., Kulshrestha, S., Navaneethan, S., Perkovic, V., Strippoli, G., Zoungas, S. (2009). Interventions for lowering plasma homocysteine levels in dialysis patients. Cochrane Database of Systematic Reviews, 2, 1-12. [More Information]
  • Kang, A., Nigwekar, S., Perkovic, V., Kulshrestha, S., Zoungas, S., Navaneethan, S., Cass, A., Gallagher, M., Ninomiya, T., Strippoli, G., et al (2009). Interventions for lowering plasma homocysteine levels in kidney transplant recipients [Protocol]. Cochrane Database of Systematic Reviews, (3), 1-12. [More Information]
  • White, S., Perkovic, V., Cass, A., Chang, C., Poulter, N., Spector, T., Haysom, L., Craig, J., Al Salmi, I., Chadban, S., Huxley, R. (2009). Is Low Birth Weight an Antecedent of CKD in Later Life? A Systematic Review of Observational Studies. American Journal of Kidney Diseases, 54(2), 248-261. [More Information]
  • Perkovic, V., Jardine, M., Gallagher, M., Cass, A. (2009). Lipid lowering in chronic kidney disease. In A.M. Tonkin (Eds.), Therapeutic Strategies in Lipid Disorders, (pp. 135-142). United Kingdom: Clinical Publishing, Oxford.
  • de Galan, B., Perkovic, V., Ninomiya, T., Pillai, A., Patel, A., Cass, A., Neal, B., Poulter, N., Harrap, S., Mogensen, C., Woodward, M., MacMahon, S., Chalmers, J., et al (2009). Lowering Blood Pressure Reduces Renal Events in Type 2 Diabetes. Journal of the American Society of Nephrology, 20(4), 883-892. [More Information]
  • Ninomiya, T., Perkovic, V., Verdon, C., Barzi, F., Cass, A., Gallagher, M., Jardine, M., Anderson, C., Chalmers, J., Craig, J., Huxley, R. (2009). Proteinuria and Stroke: A Meta-analysis of Cohort Studies. American Journal of Kidney Diseases, 53(3), 417-425. [More Information]
  • Lambers Heerspink, H., Perkovic, V., de Zeeuw, D. (2009). Renal and cardio-protective effects of direct renin inhibition: a systematic literature review. Journal of Hypertension, 27(12), 2321-2331. [More Information]
  • Perkovic, V., Ninomiya, T., MacMahon, S., Chalmers, J. (2009). Renal and microalbuminuria data from ADVANCE. In Bernard I. Levy, Harry A.J. Struijker-Boudier (Eds.), Role of Macro and Microcirculation in Target Organ Damage in Diabetes and Hypertension, (pp. 121-132). West Sussex: Wiley-Blackwell Publishing.
  • Joshi, R., de Galan, B., Chalmers, J., Perkovic, V., Patel, A. (2009). Routine blood pressure lowering and intense glucose control in patients with type 2 diabetes: results from the ADVANCE trial. Expert Review of Endocrinology & Metabolism, 4(2), 111-118.
  • Zoungas, S., Ninomiya, T., Huxley, R., Cass, A., Jardine, M., Gallagher, M., Patel, A., Vasheghani-Farahani, A., Sadigh, G., Perkovic, V. (2009). Systematic review: sodium bicarbonate treatment regimens for the prevention of contrast-induced nephropathy. Annals of Internal Medicine, 151(9), 631-638. [More Information]

2008

  • Perkovic, V. (2008). Anaemia management and EBM: What have we learned? Australian Clinical Nephrology Symposium 2008, Not-Known.
  • Craig, J., Perkovic, V., Chadban, S., Cass, A., McDonald, S., Salkeld, G., Howard, K., White, S. (2008). Cost effectiveness of screening for the early diagnosis and treatment of risk factors for chronic kidney disease: a Markov Monte Carlo microsimulation using marck-E (model for the assessment of risk factors for chronic kidney disease - economics). 42nd Australia and New Zealand Society of Nephrology Annual Scientific Conference (2006), United States of America: Wiley-Blackwell Publishing.
  • Perkovic, V. (2008). Diabetes, Kidney Disease and Cardiovascular disease workshop. AstraZeneca Cardiovascular Specialist Symposium 2008, Not-Known.
  • Turnbull, F., Woodward, M., Neal, B., Barzi, F., Ninomiya, T., Chalmers, J., Perkovic, V., Li, N., MacMahon, S. (2008). Do men and women respond differently to blood pressure-lowering treatment? Results of prospectively designed overviews of randomized trials. European Heart Journal, 29(21), 2669-2680. [More Information]
  • Turnbull, F., Neal, B., Ninomiya, T., Algert, C., Arima, H., Barzi, F., Bulpitt, C., Chalmers, J., Fagard, R., Gleason, A., Heritier, S., Perkovic, V., Woodward, M., MacMahon, S., et al (2008). Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ: British Medical Journal, 336(6753), 1121-1123. [More Information]
  • Strippoli, G., Navaneethan, S., Perkovic, V., Pellegrini, F., Nicolucci, A., Johnson, D., Craig, J. (2008). Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials. BMJ: British Medical Journal, 336(7645), 1-14. [More Information]
  • Perkovic, V., Cass, A., Patel, A., Suriyawongpaisal, P., Barzi, F., Chadban, S., MacMahon, S., Neal, B. (2008). High prevalence of chronic kidney disease in Thailand. Kidney International, 73(4), 473-479. [More Information]
  • Patel, A., MacMahon, S., Chalmers, J., Neal, B., Billot, L., Woodward, M., Marre, M., Cooper, M., Glasziou, P., Grobbee, D., Joshi, R., et al (2008). Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. New England Journal of Medicine, 358(24), 2560-2572. [More Information]
  • Ninomiya, T., Perkovic, V., Gallagher, M., Jardine, M., Cass, A., Arima, H., Anderson, C., Neal, B., Woodward, M., Omae, T., MacMahon, S., Chalmers, J. (2008). Lower blood pressure and risk of recurrent stroke in patients with chronic kidney disease: PROGRESS trial. Kidney International, 73(8), 963-970. [More Information]
  • Chalmers, J., Colagiuri, S., Cooper, M., Grobbee, R., Hamet, P., Kengne, A., MacMahon, S., Marre, M., Mogensen, C., Neal, B., Patel, A., Perkovic, V., et al (2008). Prevention of vascular outcomes in type 2 diabetes: benefits of intensive blood pressure and blood glucose control with Preterax and Diamicron MR. France: Wolters Kluwer Health France.
  • White, S., McGeechan, K., Jones, M., Cass, A., Chadban, S., Polkinghorne, K., Perkovic, V., Roderick, P. (2008). Socioeconomic Disadvantage and Kidney Disease in the United States, Australia, and Thailand. American Journal of Public Health, 98(7), 1306-1313. [More Information]
  • Perkovic, V. (2008). Specific Consideration in etiology and risk factor of ESKD in Asia. 2nd Meeting of the Asian forum of CDK Initiative, Not-Known.
  • Perkovic, V., Verdon, C., Ninomiya, T., Barzi, F., Cass, A., Patel, A., Jardine, M., Gallagher, M., Turnbull, F., Chalmers, J., Craig, J., Huxley, R. (2008). The relationship between proteinuria and coronary risk: a systematic review and meta-analysis. PLoS Medicine, 5(10), 1486-1495. [More Information]

2007

  • Perkovic, V., Ninomiya, T., Arima, H., Jardine, M., Cass, A., Neal, B., MacMahon, S., Chalmers, J. (2007). Chronic Kidney Disease, Cardiovascular Events, and The Effects Of Perindopril-Based Blood Pressure Lowering: Data From The PROGRESS Study. Journal of the American Society of Nephrology, 18(10), 2766-2772. [More Information]
  • Chalmers, J., Colagiuri, S., Grobbee, R., Hamet, P., Kengne, A., MacMahon, S., Mogensen, C., Neal, B., Patel, A., Perkovic, V., et al (2007). New approaches for the prevention of vascular disease in type 2 diabetes: benefits of blood pressure lowering with the fixed combination of perindopril and indapamide. France: Wolters Kluwer Health Pharma Solutions.
  • Chalmers, J., Kengne, A., Joshi, R., Perkovic, V., Patel, A. (2007). New insights from ADVANCE. Journal of Hypertension, 25(Suppl. 1), S23-S30. [More Information]

2006

  • Chalmers, J., Perkovic, V., Joshi, R., Patel, A. (2006). ADVANCE: breaking new ground in type 2 diabetes. Journal of Hypertension, 24(Supplement 5), S22-S28. [More Information]
  • Perkovic, V., Joshi, R., Patel, A., Bompoint, S., Chalmers, J., Neal, B., MacMahon, S., Glasziou, P., Woodward, M., Cooper, M., et al (2006). ADVANCE: Lessons from the run-in phase of a large study in type 2 diabetes. Blood Pressure, 15(6), 340-346. [More Information]
  • Howard, K., Salkeld, G., White, S., Chadban, S., Craig, J., Cass, A., McDonald, S., Perkovic, V. (2006). Cost effectiveness of screening for the early diagnosis and treatment of risk factors for chronic kidney disease: A Markov Monte Carlo microsimulation using Marck-E. 42nd Annual Scientific Meeting of the Australian and New Zealand Society of Nephrology.
  • Gallagher, M., Perkovic, V., Chalmers, J. (2006). Diuretics: A modern day treatment option? (Review Article). Nephrology, 11(5), 419-427. [More Information]
  • Howard, K., Salkeld, G., White, S., Chadban, S., Craig, J., McDonald, S., Perkovic, V., Cass, A. (2006). The cost-effectiveness of early detection and intervention to prevent the progression of Chronic Kidney Disease in Australia.
  • Howard, K., Salkeld, G., White, S., Chadban, S., Craig, J., McDonald, S., Perkovic, V., Cass, A. (2006). The Cost-Effectiveness of Early Detection and Intervention to Prevent the Progression of Chronic Kidney Disease in Australia.

2005

  • Kerr, P., Perkovic, V., Petrie, J., Agar, J., Disney, A. (2005). Dose of haemodialysis. Nephrology, 10, S61-3. [More Information]

2003

  • Perkovic, V., Hewitson, T., Kelynack, K., Martic, M., Tait, M., Becker, G. (2003). Parathyroid hormone has a prosclerotic effect on vascular smooth muscle cells. Kidney and Blood Pressure Research, 26(1), 27-33. [More Information]

To update your profile click here. For support on your academic profile contact .